PMP/DEGESCO
To create a global strategy to identify Alzheimer’s disease cases in prodromal and preclinical stages through a nationwide web platform that progressively integrates precision medicine techniques into diagnostic algorithms, with the participation of 14 memory clinics from 8 regions of Spain.
The PMP-DEGESCO project (Precision Medicine Project – Dementia Genetics Spanish Consortium) is a Spanish initiative aimed at developing a precision medicine tool to detect Alzheimer’s disease in very early stages. It is funded by the Recovery, Transformation and Resilience Plan through Next Generation EU funds. Coordination is led by the Carlos III Health Institute (ISCIII) within the Personalized Precision Medicine Program.
Three main elements define the proposal. First, an online cognitive evaluation makes it possible to remotely assess memory and other mental functions. Second, genetic risk stratification analyzes genetic variants to estimate an individual’s predisposition to develop the disease. Finally, blood-based biomarkers are used to detect biological changes related to Alzheimer’s before clinical symptoms appear.
All these components converge in a single tool. The goal is to create an accessible, scalable, and low-cost prediction system. Designed for the Spanish National Health System, this approach will bring early detection closer to the general population.
Research centers and hospitals from across Spain are actively involved, forming a multicenter network. Thanks to this collaboration, the collected data represent a broad and diverse population. Tests are carried out following standardized protocols, and the results are stored securely, with strict adherence to ethical and confidentiality standards.
The expected impact is considerable. PMP-DEGESCO will allow the identification of Alzheimer’s in its earliest phases, when therapeutic options are most promising. It will also strengthen national research in neuroscience and pave the way for future preventive interventions.
In short, PMP-DEGESCO represents a decisive step toward a more personalized and preventive medicine. It will contribute both to early diagnosis and to the development of innovative therapeutic strategies against a disease that affects millions of people worldwide.